US Patent Issued to Northwestern University, The University of Chicago on Oct. 14 for "Agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy" (Illinois Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,440,476, issued on Oct. 14, was assigned to Northwestern University (Evanston, Ill.) and The University of Chicago (Chicago).

"Agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy" was invented by Karl A. Scheidt (Evanston, Ill.), Stephen J. Kron (Chicago) and Yue Liu (Chicago).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject in need thereof, the met...